Association Between Venlafaxine Exposure And Treatment Outcomes In Older Adults With Depression: Association entre l’exposition à la venlafaxine et les résultats du traitement chez les personnes âgées atteintes de dépression
The Canadian Journal of Psychiatry · 2026-09 · 71 (9) · 691-702
DOI: 10.1177/07067437261451057 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Canadian Journal of Psychiatry, online erschienen am 14.05.2026. Verfasst von Xiaoyu Men und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Venlafaxine Hydrochloride, Outcome Assessment, Health Care, Serotonin and Noradrenaline Reuptake Inhibitors, Major Depressive Disorder. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Taylor Family Institute for Innovative Psychiatric Research, School of Medicine, Washington University in St. Louis, Washington University Institute of Clinical and Translational Sciences, Campbell Family Mental Health Research Institute.
Themen: Gerontologische Pflege, Depression
Abstract (Originalsprache)
Background
Venlafaxine is commonly prescribed for older adults with depression, yet the relationship between venlafaxine-related exposure and treatment outcomes remains unclear. We aimed to assess the association of exposure to venlafaxine, its active metabolite O-desmethylvenlafaxine (ODV) and its active moiety (i.e., venlafaxine + ODV) with treatment response and adverse effects in late-life depression.
Method
We analyzed data from 325 participants from the Incomplete Response in Late-Life Depression: Getting to Remission (IRL-GRey) study. Participants were ≥ 60 years old, treated openly with venlafaxine (up to 300 mg/day) for 12 weeks. Treatment response was assessed with the Montgomery–Asberg Depression Rating Scale and adverse effects were evaluated with the Udvalg for Kliniske Undersøgelser (UKU) rating scale. Venlafaxine-related exposures were derived from a published population pharmacokinetic model based on the IRL-GRey study, and their associations with treatment outcomes were assessed using regression analyses.
Result
At week 4, the primary endpoint, higher venlafaxine-related exposures were not associated with greater symptom improvement. While at the end of treatment (week 12), we did not observe additional antidepressant benefit with increased venlafaxine-related exposures, higher ODV and active moiety exposures were associated with the occurrence of at least one adverse effect (odds ratio [OR] = 1.6 [1.1, 2.3], p = 0.02 and 1.8 [1.2, 2.6], p = 0.003, respectively). Also, higher venlafaxine and active moiety exposures were associated with nausea/vomiting (OR = 1.1 [1.0, 1.2], p = 0.02 and 2.3 [1.3, 4.0], p = 0.006); while higher active moiety exposure was associated with orthostatic dizziness (OR = 1.9 [1.1, 3.2], p = 0.02).
Conclusion
Our findings suggest a potential threshold effect, where venlafaxine-related exposure past a certain level did not enhance antidepressant response but increased adverse-effect burden. These results support incorporating exposure measures from therapeutic drug monitoring in antidepressant studies to address the heterogeneity of safety and tolerability outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Center for Translational and Computational Neuroimmunology, Columbia University Medical Center, New York, New York, USA.
ORCID-Profile: Xiaoyu Men, Daniel M Blumberger, Jordan F Karp, James L Kennedy, Laura B Ramsey, Benoit H Mulsant, Daniel J Müller
Förderung
- Taylor Family Institute for Innovative Psychiatric Research, School of Medicine, Washington University in St. Louis
- Washington University Institute of Clinical and Translational Sciences
- Campbell Family Mental Health Research Institute
- UPMC Endowment in Geriatric Psychiatry
- National Institute of Mental Health
Zitieren
APA
Men, X., Taylor, Z. L., Marshe, V. S., Blumberger, D. M., Karp, J. F., Kennedy, J. L., Stefan, C., Ramsey, L. B., Lenze, E. J., Reynolds, C. F., Mulsant, B. H., & Müller, D. J. (2026). Association Between Venlafaxine Exposure And Treatment Outcomes In Older Adults With Depression: Association entre l’exposition à la venlafaxine et les résultats du traitement chez les personnes âgées atteintes de dépression. The Canadian Journal of Psychiatry, 71(9), 691-702. https://doi.org/10.1177/07067437261451057
Vancouver
Men X, Taylor ZL, Marshe VS, Blumberger DM, Karp JF, Kennedy JL, et al. Association Between Venlafaxine Exposure And Treatment Outcomes In Older Adults With Depression: Association entre l’exposition à la venlafaxine et les résultats du traitement chez les personnes âgées atteintes de dépression. The Canadian Journal of Psychiatry. 2026;71(9):691-702. doi:10.1177/07067437261451057
BibTeX
@article{Men2026,
author = {Men, Xiaoyu and Taylor, Zachary L and Marshe, Victoria S and Blumberger, Daniel M and Karp, Jordan F and Kennedy, James L and Stefan, Cristiana and Ramsey, Laura B and Lenze, Eric J and Reynolds, Charles F and Mulsant, Benoit H and Müller, Daniel J},
title = {Association Between Venlafaxine Exposure And Treatment Outcomes In Older Adults With Depression: Association entre l’exposition à la venlafaxine et les résultats du traitement chez les personnes âgées atteintes de dépression},
journal = {The Canadian Journal of Psychiatry},
year = {2026},
volume = {71},
number = {9},
pages = {691--702},
doi = {10.1177/07067437261451057}
}
EUVIMED